|
|
| Line 3: |
Line 3: |
| | <StructureSection load='4u04' size='340' side='right'caption='[[4u04]], [[Resolution|resolution]] 2.48Å' scene=''> | | <StructureSection load='4u04' size='340' side='right'caption='[[4u04]], [[Resolution|resolution]] 2.48Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4u04]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4U04 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4U04 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4u04]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4U04 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4U04 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand=TAR:D(-)-TARTARIC+ACID'>TAR</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand=TAR:D(-)-TARTARIC+ACID'>TAR</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">FICD, HIP13, HYPE, UNQ3041/PRO9857 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4u04 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4u04 OCA], [https://pdbe.org/4u04 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4u04 RCSB], [https://www.ebi.ac.uk/pdbsum/4u04 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4u04 ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4u04 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4u04 OCA], [http://pdbe.org/4u04 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4u04 RCSB], [http://www.ebi.ac.uk/pdbsum/4u04 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4u04 ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/FICD_HUMAN FICD_HUMAN]] Adenylyltransferase that mediates the addition of adenosine 5'-monophosphate (AMP) to specific residues of target proteins. Able to inactivate Rho GTPases in vitro by adding AMP to RhoA, Rac and Cdc42. It is however unclear whether it inactivates GTPases in vivo and physiological substrates probably remain to be identified.<ref>PMID:19362538</ref> <ref>PMID:22266942</ref> | + | [https://www.uniprot.org/uniprot/FICD_HUMAN FICD_HUMAN] Adenylyltransferase that mediates the addition of adenosine 5'-monophosphate (AMP) to specific residues of target proteins. Able to inactivate Rho GTPases in vitro by adding AMP to RhoA, Rac and Cdc42. It is however unclear whether it inactivates GTPases in vivo and physiological substrates probably remain to be identified.<ref>PMID:19362538</ref> <ref>PMID:22266942</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 21: |
Line 20: |
| | | | |
| | ==See Also== | | ==See Also== |
| - | *[[Fic protein|Fic protein]] | + | *[[Fic protein 3D structures|Fic protein 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Bunney, T D]] | + | [[Category: Bunney TD]] |
| - | [[Category: Cole, A R]] | + | [[Category: Cole AR]] |
| - | [[Category: Katan, M]] | + | [[Category: Katan M]] |
| - | [[Category: Adenylation]]
| + | |
| - | [[Category: Fic]]
| + | |
| - | [[Category: Tpr]]
| + | |
| - | [[Category: Transferase]]
| + | |
| Structural highlights
Function
FICD_HUMAN Adenylyltransferase that mediates the addition of adenosine 5'-monophosphate (AMP) to specific residues of target proteins. Able to inactivate Rho GTPases in vitro by adding AMP to RhoA, Rac and Cdc42. It is however unclear whether it inactivates GTPases in vivo and physiological substrates probably remain to be identified.[1] [2]
Publication Abstract from PubMed
Protein AMPylation, the transfer of AMP from ATP to protein targets, has been recognized as a new mechanism of host-cell disruption by some bacterial effectors that typically contain a FIC-domain. Eukaryotic genomes also encode one FIC-domain protein, HYPE, which has remained poorly characterized. Here we describe the structure of human HYPE, solved by X-ray crystallography, representing the first structure of a eukaryotic FIC-domain protein. We demonstrate that HYPE forms stable dimers with structurally and functionally integrated FIC-domains and with TPR-motifs exposed for protein-protein interactions. As HYPE also uniquely possesses a transmembrane helix, dimerization is likely to affect its positioning and function in the membrane vicinity. The low rate of autoAMPylation of the wild-type HYPE could be due to autoinhibition, consistent with the mechanism proposed for a number of putative FIC AMPylators. Our findings also provide a basis to further consider possible alternative cofactors of HYPE and distinct modes of target-recognition.
Crystal Structure of the Human, FIC-Domain Containing Protein HYPE and Implications for Its Functions.,Bunney TD, Cole AR, Broncel M, Esposito D, Tate EW, Katan M Structure. 2014 Nov 25. pii: S0969-2126(14)00334-7. doi:, 10.1016/j.str.2014.10.007. PMID:25435325[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Worby CA, Mattoo S, Kruger RP, Corbeil LB, Koller A, Mendez JC, Zekarias B, Lazar C, Dixon JE. The fic domain: regulation of cell signaling by adenylylation. Mol Cell. 2009 Apr 10;34(1):93-103. doi: 10.1016/j.molcel.2009.03.008. PMID:19362538 doi:http://dx.doi.org/10.1016/j.molcel.2009.03.008
- ↑ Engel P, Goepfert A, Stanger FV, Harms A, Schmidt A, Schirmer T, Dehio C. Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins. Nature. 2012 Jan 22;482(7383):107-10. doi: 10.1038/nature10729. PMID:22266942 doi:10.1038/nature10729
- ↑ Bunney TD, Cole AR, Broncel M, Esposito D, Tate EW, Katan M. Crystal Structure of the Human, FIC-Domain Containing Protein HYPE and Implications for Its Functions. Structure. 2014 Nov 25. pii: S0969-2126(14)00334-7. doi:, 10.1016/j.str.2014.10.007. PMID:25435325 doi:http://dx.doi.org/10.1016/j.str.2014.10.007
|
